Shots:

• Turning Point to receive $25M as upfront- $151M as development- regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive rights to develop and commercialize repotrectinib in Greater China including China- Hong Kong- Macau- and Taiwan
• Zai Lab anticipates opening additional sites for the TRIDENT-1 P-II registrational clinical study of repotrectinib- currently active in 11 countries globally and enrolling patients with ROS1-positive advanced NSCLC and NTRK-positive solid tumors
• The collaboration strengthens Zai Lab solid tumor’s pipeline in China- particularly in lung cancer. Repotrectinib is an investigational TKI designed to effectively target ROS1 and TRK A/B/C with potential to treat TKI-naïve or -pretreated patients

Click here to read full press release/ article | Ref: PRNewswire | Image: Businesswire